QS Investors LLC held its stake in Luminex Corporation (NASDAQ:LMNX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 45,020 shares of the medical instruments supplier’s stock at the end of the second quarter. QS Investors LLC owned 0.10% of Luminex Corporation worth $951,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Bank of America Corp DE grew its stake in Luminex Corporation by 9.9% in the 1st quarter. Bank of America Corp DE now owns 322,154 shares of the medical instruments supplier’s stock valued at $5,917,000 after purchasing an additional 29,107 shares during the period. State Street Corp grew its stake in Luminex Corporation by 13.0% in the 1st quarter. State Street Corp now owns 1,009,789 shares of the medical instruments supplier’s stock valued at $18,548,000 after purchasing an additional 116,351 shares during the period. BlackRock Inc. grew its stake in Luminex Corporation by 52,547.0% in the 1st quarter. BlackRock Inc. now owns 5,063,064 shares of the medical instruments supplier’s stock valued at $93,008,000 after purchasing an additional 5,053,447 shares during the period. Marshall Wace North America L.P. grew its stake in Luminex Corporation by 6.8% in the 2nd quarter. Marshall Wace North America L.P. now owns 88,236 shares of the medical instruments supplier’s stock valued at $1,853,000 after purchasing an additional 5,584 shares during the period. Finally, Karp Capital Management Corp bought a new position in Luminex Corporation in the 1st quarter valued at $225,000. Hedge funds and other institutional investors own 77.95% of the company’s stock.
In related news, Director Robert J. Cresci sold 19,631 shares of Luminex Corporation stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total value of $372,596.38. Following the completion of the sale, the director now owns 260,358 shares of the company’s stock, valued at $4,941,594.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.
Luminex Corporation (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The company had revenue of $76.50 million during the quarter, compared to analyst estimates of $75.45 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. Luminex Corporation’s revenue was up 19.2% compared to the same quarter last year. Analysts anticipate that Luminex Corporation will post $0.53 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 22nd will be issued a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Thursday, September 21st. Luminex Corporation’s payout ratio is currently 75.00%.
A number of brokerages have issued reports on LMNX. TheStreet downgraded Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. BidaskClub downgraded Luminex Corporation from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. ValuEngine upgraded Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, Zacks Investment Research upgraded Luminex Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective for the company in a research note on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $20.00.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Corporation (NASDAQ:LMNX).
What are top analysts saying about Luminex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Luminex Corporation and related companies.